Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Visabl.com, a cloud-based antibody and biomarker search engine, announced its largest website update. The latest iteration of the Visabl website features several enhancements and improvements to the site and user interface, including a faster targeted search of biomarkers and the ability to dynamically sort and populate results as the user types.
Sekisui Diagnostics launched the Sekure brand of clinical chemistry reagents. Sekisui develops, manufactures, and supplies clinical chemistry reagents and systems to the in vitro diagnostics industry, selling more than 1.5 billion clinical chemistry tests per year.
EDP Biotech has entered into distribution agreements with more than 25 distribution channel partners throughout Europe, Asia, and South America. EDP plans a multiphase rollout of ColoMarker, a blood test that aids in the detection of early stage colorectal cancer, in 2015 to gain experience and data in conjunction with key opinion leaders and distributor partners.
Copan has obtained FDA clearance for its FecalSwab, which comprises a regular size Copan flocked swab (FloqSwab) and a screw-cap tube containing 2 mL of Cary-Blair medium. FecalSwab is intended for the collection of rectal swabs and fecal specimens and to preserve the viability of enteric pathogenic bacteria during transport from the collection site to the testing laboratory.
Bruker has announced what it says is a major expansion of its Mycobacteria Library for research use only on the MALDI Biotyper microbial mass spectrometry system.
The Institute for Life Science Entrepreneurship and ATCC will collaborate to establish the ATCC Center for Translational Microbiology at ILSE. The focus of the center will be on key challenges identified by both ATCC and ILSE in current translational microbiology, including antimicrobial resistance, synthetic biology, microbial bioinformatics, and the microbiome.
Microbiologics has launched a Business Solutions division dedicated to partnering with diagnostic and life science technology manufacturers. Users of these instruments and assays need biological controls to meet regulatory requirements for validation, verification, and quality control.
InSphero released its GravityTrap Ultra-low Attachment (ULA) Plate. The automation-compatible 96-well ULA format is well suited for production of 3-D tumor microtissues derived from tumor cell lines or to screen for the propensity of cells to form spheroids in a low-attachment environment.
Great Basin Scientific announced the FDA clearance and commercial availability of its molecular diagnostic test for group B streptococcus. The group B strep assay provides accurate results in approximately 90 minutes with a specimen from enriched LIM broth. By targeting a highly conserved region of the cfb (CAMP factor) gene, the molecular assay provides definitive identification and a more rapid diagnosis of the mother’s GBS colonization status compared to standard culture-based tests, which may take up to an additional 48 hours.
Horizon Discovery Group and Transgenomic announced a new original equipment manufacturer agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed.
